2023-03-09 07:12:36 ET
- Fulcrum Therapeutics press release ( NASDAQ: FULC ): Q4 GAAP EPS of -$0.50 misses by $0.01 .
- Revenue of $0.7M (-86.2% Y/Y) misses by $1.19M .
- As of December 31, 2022, cash, cash equivalents and marketable securities were $202.9 million as compared to $218.2 million as of December 31, 2021.
- Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2025.
For further details see:
Fulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19M